Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01417299
Other study ID # 0260-11-HMO
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received August 15, 2011
Last updated September 20, 2015
Start date October 2011
Est. completion date October 2018

Study information

Verified date August 2011
Source Hadassah Medical Organization
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

The investigators are studying the impact of RPh201 on chronic vegetative patients. RPh201 has been reported to induce neuronal regeneration in animal models. Evaluation will be done by combining clinical /behavioral assessment with fMRI studies.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date October 2018
Est. primary completion date October 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Chronic vegetative patients

Exclusion Criteria:

- Inability to go through an MRI scans (i.e. metal implants, neurotransmitters)and pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
RPh201
Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
saline
Patients will receive 400 microliter s.c., of saline twice a week for 3 months

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hadassah Medical Organization

Outcome

Type Measure Description Time frame Safety issue
Primary change in the awareness status of the patients. Clinical and laboratory assessment will be done every two weeks along the treatment period fMRI assessment will be performed 3 times: before the treatment, immediate afterwards and one month following treatment cessation. 3-6 months Yes
Secondary change in the awareness status of the patients. clinical and fMRI assessment will be performed 1 month following treatment cessation 1 month following the end of the trial Yes
See also
  Status Clinical Trial Phase
Suspended NCT01438684 - The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study Phase 1